News and Trends 6 Jul 2022 Finnish and US companies form exclusive agreement for development of sustained release drug …GA, met its pre-specified primary efficacy endpoint with statistical significance. The most frequently reported ocular adverse events in this trial were related to the injection procedure. Clinical trial The Company… July 6, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 4 Dec 2023 FDA CAR-T cell therapy warning: Are T cells malignant? …6 products: · Abecma – Bristol Myers Squibb · Breyanzi – Bristol Myers Squibb · Carvykti – Jannsen (J&J) and Legend Biotech · Kymriah – Novartis… December 4, 2023 - 4 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug …of 2023 upon the completion of requested toxicology studies, then starting its phase 1 program by the end of 2023. Tiziana is a U.S. biotechnology company developing immunomodulation therapies via… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2023 The ongoing search for an HIV cure: can CRISPR crack the code? …feasibility of genetically-edited stem cell transplantation for AIDS treatment,” he said. In fact, he referred to it as a success because the scientists didn’t detect any gene editing-related adverse events,… October 30, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 8 Dec 2023 Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Table of contents The latest biotech news in… December 8, 2023 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Astellas menopause study meets endpoints but leukemia drug disappoints …52-week study period. During the double-blind period, treatment-emergent adverse events (TEAEs) occurred in 37% of fezolinetant 30 mg, 43% of 45 mg and 45% of placebo participants. The safety profile… March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jan 2020 Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany …be payable each year depending on whether the therapy prevents the need for transfusions completely. This value-based installment system is also in use for other advanced treatments such as Spark’s… January 14, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization …challenge for the pharmaceutical and biotech industries to meet regulatory requirements. “Product characterization activities must begin in preclinical development and continue throughout the entire development process to marketing introduction,” said… September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2021 A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology …while fatal toxic events were similar for both therapies. According to the study, the death rate for both therapies was 5.4%. As a comparison, that of immune checkpoint therapy lies… October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 Astellas meets primary endpoint in gastric cancer study …survival (OS), showing statistical significance for patients treated with zolbetuximab plus mFOLFOX6 compared to placebo plus mFOLFOX6. The most frequent treatment-emergent adverse events (TEAEs) in patients treated with zolbetuximab plus… November 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Concern as study says new covid sub-variant is resistant to all therapeutic antibodies …antibodies protect by binding to the viral spike protein, which prevents the virus from entering cells. However, due to mutations in the spike protein, some SARS-CoV-2 variants, particularly the Omicron… November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2023 Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities …stay in the program. But the events that led to the U.K. rejoining the research program being stalled indefinitely, occurred post-Brexit. Initially, as part of the Brexit deal, it was… September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email